BML Investment Partners Amends CalciMedica Stake
Ticker: CALC · Form: SC 13G/A · Filed: Feb 7, 2024 · CIK: 1534133
| Field | Detail |
|---|---|
| Company | Calcimedica, INC. (CALC) |
| Form Type | SC 13G/A |
| Filed Date | Feb 7, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech
TL;DR
**BML Investment Partners still holds CalciMedica shares, signaling continued institutional interest.**
AI Summary
BML Investment Partners, L.P. filed an amended Schedule 13G/A on February 7, 2024, indicating their ownership of CalciMedica, Inc. common stock as of December 31, 2023. This amendment updates their previous filing, showing their continued significant stake in the pharmaceutical company. This matters to investors because BML Investment Partners, L.P. is a substantial institutional investor, and their ongoing position suggests confidence in CalciMedica's future, potentially influencing other investors' perceptions of the stock.
Why It Matters
This filing shows that a major institutional investor, BML Investment Partners, L.P., continues to hold a significant position in CalciMedica, Inc., which can be seen as a vote of confidence in the company's prospects.
Risk Assessment
Risk Level: low — This is an informational filing about an existing stake, not a new investment or divestment, so it presents low immediate risk.
Analyst Insight
Investors should note that BML Investment Partners, L.P. maintains its position in CalciMedica, Inc. This suggests continued confidence from a significant institutional holder, which could be a positive signal, but further research into the company's fundamentals and recent performance is warranted before making investment decisions.
Key Players & Entities
- BML Investment Partners, L.P. (company) — the reporting person filing the SC 13G/A
- CalciMedica, Inc. (company) — the issuer of the securities
- December 31, 2023 (date) — the date of the event requiring the filing
- February 7, 2024 (date) — the filing date of the SC 13G/A
- $0.0001 (dollar_amount) — par value per share of CalciMedica common stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by the 'FORM TYPE: SC 13G/A' and 'AMENDMENT NO. 1' in the filing.
Who is the reporting person in this filing?
The reporting person is BML Investment Partners, L.P., as stated under 'NAMES OF REPORTING PERSONS' on the cover page.
What is the subject company (issuer) of the securities?
The subject company, or issuer, is CalciMedica, Inc., as identified under 'Name of Issuer' and 'COMPANY CONFORMED NAME: CalciMedica, Inc.'.
What is the CUSIP number for the securities reported?
The CUSIP number for the Common Stock, par value $0.0001 per share, is 38942Q202, as listed on the cover page of the filing.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified on the cover page.
Filing Stats: 975 words · 4 min read · ~3 pages · Grade level 8.4 · Accepted 2024-02-07 11:14:29
Key Financial Figures
- $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie
Filing Documents
- calc13g020724.htm (SC 13G/A) — 76KB
- 0001616824-24-000023.txt ( ) — 77KB
(a)
Item 1(a). Name of Issuer: CalciMedica, Inc.
(b)
Item 1(b). Address of Issuer's Principal Executive Offices: 505 Coast Boulevard South, Suite 307 La Jolla, California 92037.
(a)
Item 2(a). Name of Person Filing: BML Investment Partners, L.P.
(b)
Item 2(b). Address of Principal Business Office or, if none, Residence: 65 E Cedar - Suite 2 Zionsville, IN 46077
(c)
Item 2(c). Citizenship: Delaware
(d)
Item 2(d). Title of Class of Securities: Common Stock
(e)
Item 2(e). CUSIP Number: 38942Q202 Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n): (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ . Item 4. (a) Amount beneficially owned: 220,424 (b) Percent of class: (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 75,000 (ii) Shared power to vote or to direct the vote: 145,424 (iii) Sole power to dispose or to direct the disposition of: 75,000 (iv) Shared power to dispose or to direct the disposition of: 145,424 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class